CORMEDIX INC. Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31)
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CORMEDIX INC. development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for the quarter ending 2014-12-31 was $0.00.
- CORMEDIX INC. development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for the quarter ending 2014-09-30 was $0.00.
- CORMEDIX INC. development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for the quarter ending 2014-06-30 was -$1.73M.
- CORMEDIX INC. development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for the quarter ending 2014-03-31 was $6.72M.
- CORMEDIX INC. development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for fiscal 2014 was $4.99M.
| Period end | Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31) 3 month | Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31) 12 month |
|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $4.99M 10-K · filed 2015-03-12 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | |
| 2014-06-30 | -$1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | |
| 2014-03-31 | $6.72M 10-Q · filed 2014-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |